Antiviral Resistance against Viral Mutation: Praxis and Policy for SARS-CoV-2
Tools developed by Moderna, BioNTech/Pfizer, and Oxford/Astrazeneca, among others, provide universal solutions to previously problematic aspects of drug or vaccine delivery, uptake and toxicity, portending new tools across the medical sciences. A novel method is presented based on estimating protein...
Guardado en:
Autor principal: | Penner Robert |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d8f1b8f6200c425c8f397dbbc6e2091b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Low temperatures or high isolation delay increases the average COVID-19 infections in India : A Mathematical modeling approach
por: Prakash D Bhanu, et al.
Publicado: (2021) -
A Study of Within-Host Dynamics of Dengue Infection incorporating both Humoral and Cellular Response with a Time Delay for Production of Antibodies
por: Kanumoori Deva Siva Sai Murari, et al.
Publicado: (2021) -
Optimal Control of a Dengue-Dengvaxia Model: Comparison Between Vaccination and Vector Control
por: Mentuda Cheryl Q.
Publicado: (2021) -
Modelling of a two prey and one predator system with switching effect
por: Saha Sangeeta, et al.
Publicado: (2021) -
Impact of fear in a prey-predator system with herd behaviour
por: Saha Sangeeta, et al.
Publicado: (2021)